http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
AbbVie to Host First-Quarter 2024 Earnings Conference Call
-
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
-
AbbVie (ABBV) to Acquire Landos Biopharma (LABP) for $20.42/Share
-
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
-
AbbVie (ABBV) Confirms FDA Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
-
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
-
ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024
-
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
-
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
-
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
-
AbbVie (ABBV) Announces JUVEDERM VOLUMA XC For Temple Hollows Receives U.S. FDA Approval
-
JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
-
AbbVie (ABBV) Pays Milestone to Dragonfly Following Dosing of First Patient in Phase 1 Trial of DF4101/ABBV-303
-
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
-
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
-
AbbVie (ABBV) partners with OSE Immunotherapeutics to develop Novel Monoclonal Antibody
-
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
-
AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
-
U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
-
Genmab (GMAB) FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
-
AbbVie (ABBV) and Tentarix Collaborate Over Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
-
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
-
BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs
-
AbbVie (ABBV) Appoints Robert A. Michael as CEO
-
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
-
AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
-
AbbVie Declares Quarterly Dividend
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
AbbVie (ABBV) Completes Acquisition of ImmunoGen (IMGN)
-
AbbVie Completes Acquisition of ImmunoGen
-
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
-
Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024
-
Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.
-
AbbVie (ABBV) Launches PRODUODOPA in the EU
-
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union
-
AbbVie (ABBV) Reports Lutikizumab Showed Positive Results in a Phase 2 Trial
-
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
-
AbbVie (ABBV) and Umoja Biopharma Collaborate to Develop Novel In-Situ CAR-T Cell Therapies
-
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
-
AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
-
AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
-
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
-
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $45 Per Share, $8.7 Billion Deal
-
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
-
AbbVie (ABBV), BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
-
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
-
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $31.26 Per Share, $10.1 Billion
